GlassScriptPhysician profile
Lisa Forte
NPI 1982771226
$5,632.32
in general payments reported to CMS, 2019-2025
48 companies · $1,857 in 2025
The $1,857 reported for 2025 was more than what 93% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $395 · 2022: $600 · 2023: $1,177 · 2024: $1,602 · 2025: $1,857.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,353 · Education: $284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,352.86 |
| Education | $283.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $549.62 | 2021-2025 | Darzalex, Tecvayli, Talvey |
| Astrazeneca Pharmaceuticals LP | $450.55 | 2021-2025 | Tagrisso, Calquence, Lynparza |
| Merck Sharp & Dohme LLC | $371.26 | 2022-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Regeneron Healthcare Solutions, INC. | $294.32 | 2022-2025 | Libtayo |
| Gilead Sciences, INC. | $277.09 | 2022-2025 | Trodelvy |
| Seagen INC. | $267.36 | 2021-2023 | Tukysa, Padcev |
| Amgen INC. | $243.48 | 2021-2023 | Kyprolis, Xgeva, Vectibix |
| Novartis Pharmaceuticals Corporation | $233.12 | 2022-2025 | |
| Jazz Pharmaceuticals INC. | $209.20 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $189.91 | 2023-2025 | |
| Abbvie INC. | $177.24 | 2024-2025 | |
| Daiichi Sankyo INC. | $161.51 | 2023-2025 | Enhertu |
| Beigene USA, INC. | $160.65 | 2021-2024 | Brukinsa, Tevimbra |
| Genentech USA, INC. | $160.21 | 2023-2025 | Phesgo, Perjeta, Tecentriq Hybreza |
| Genzyme Corporation | $146.47 | 2022-2025 |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $145.65 | 2022-2025 | Opdivo, Opdualag |
| Exelixis INC. | $138.70 | 2024 | Cabometyx |
| Lilly USA, LLC | $138.61 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
| Genmab U.S., INC. | $115.53 | 2023-2025 | Epkinly |
| Sanofi-Aventis U.S. LLC | $99.99 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $95.65 | 2022-2025 | Ninlaro, Iclusig |
| Tersera Therapeutics LLC | $86.79 | 2023-2025 | Zoladex |
| Incyte Corporation | $81.50 | 2021-2024 | Jakafi, Monjuvi, Pemazyre |
| Beone Medicines USA, INC. | $79.62 | 2025 | Tevimbra |
| Ipsen Biopharmaceuticals, INC | $78.47 | 2023-2024 | Onivyde, Somatuline Depot |
| Karyopharm Therapeutics INC. | $70.84 | 2023-2024 | Xpovio |
| Pfizer INC. | $57.64 | 2023-2025 | |
| Eisai INC. | $45.57 | 2022-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $40.82 | 2022-2023 | Epkinly, Imbruvica |
| Alexion Pharmaceuticals, INC. | $37.26 | 2022-2025 | Ultomiris |
| Pharmacosmos Therapeutics INC. | $36.55 | 2024-2025 | Monoferric |
| Puma Biotechnology, INC. | $34.74 | 2024-2025 | |
| Taiho Oncology, INC. | $34.37 | 2024 | |
| Aveo Pharmaceuticals, INC. | $33.05 | 2025 | |
| Rigel Pharmaceuticals, INC. | $29.30 | 2023 | Tavalisse, Rezlidhia |
| Deciphera Pharmaceuticals INC. | $26.90 | 2024 | Qinlock |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.60 | 2025 | |
| Glaxosmithkline, LLC. | $24.13 | 2024 | Ojjaara |
| Pharmaessentia USA Corporation | $23.67 | 2023 | Besremi |
| Sumitomo Pharma America, INC. | $21.96 | 2024 | Orgovyx |
| Array Biopharma INC | $20.95 | 2024 | Braftovi, Xalkori, Mektovi |
| Emd Serono, INC. | $19.61 | 2024 | |
| Janssen Pharmaceuticals, INC | $18.90 | 2023 | Xarelto |
| Agios Pharmaceuticals, INC. | $17.77 | 2024 | |
| G1 Therapeutics, INC. | $16.62 | 2022 | |
| Celgene Corporation | $16.30 | 2022 | |
| Fennec Pharmaceuticals, INC. | $15.43 | 2025 | Fyarro |
| Sobi, INC | $12.84 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Forte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.